Please assess the completion status of the following clinical trial:

Trial Title: A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CDI is confirmed by clinical symptoms (either \> 3 unformed bowel movements or ≥ 200ml of unformed stool (for subjects having rectal collection devices)) in the 24 hours prior to randomization and CDI test confirmed positive for presence of C. difficile toxin A or B in stool within 48 hr prior to randomization.~* Subject agrees not to participate in another interventional study whilst participating in this study.~Exclusion Criteria:~* Subject is taking or requiring to be treated with prohibited medications~* Subject has received more than one day of dosing of any therapy for CDI within the last 48 hours~* Subject has experienced more than 2 previous episodes of CDI in the 3 months prior to study enrolment~* Subject is unable to swallow oral study medication.~* Subject has a current diagnosis of toxic megacolon.~* Subject is not willing to adhere to the provisions of treatment and observation specified in the protocol.~* Subject has been randomized into this study previously, has taken any investigational drug within 28 days or 5 half lives, whichever is longer, prior to enrollment, or is currently participating in another clinical study which may influence the assessment of efficacy and/or safety endpoints of this study, in the opinion of the Sponsor.~* Subject has previously participated in a CDI vaccine study~* Subject has hypersensitivity to fidaxomicin, vancomycin or any of its components.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fidaxomicin Extended Pulsed Regimen (EPFX) (Type: EXPERIMENTAL): Participants receive 200 mg fidaxomicin from day 1 to day 5 twice daily, followed by a 1-day gap (day 6) before starting alternate day dosing of 1 tablet of fidaxomicin 200 mg once daily from day 7 to day 25.
- Vancomycin (Type: EXPERIMENTAL): Participants receive 125 mg vancomycin from day 1 to day 10, 4 times daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).